Nepsone is a preclinical-stage pharmaceutical company developing drugs to treat dermatological conditions that arise due to an imbalance in the autonomic nervous system.
Currently, these conditions are believed to originate in the immune system. Nepsone foundational neuroimmunology theory on the origin of psoriasis teaches us that an imbalance in neuropeptide activity in the body leads to these conditions.
Our drugs are designed to utilize the body’s natural mechanisms to bring back balance and alleviate the disease.
Nepsone ehf has been awarded a grant from Tækniþróunarsjóður (Technology Development Fund) of Rannís (The Icelandic Centre for Research).
Nepsone’s drug discovery platform can potentially address over 10 indications in total.
Phase: Preclinical
Modalities: Topical and Systemic
Phase: Research and Discovery
Modality: Topical
There are currently no approved drugs for the treatment of alopecia areata.
Phase: Research and Discovery
Modality: Topical
COO
Head of Clinical Development
Head of R&D
Head of Medical Affairs
Chairman of the board
Founder / Member of the board
Member of the board